TNG462

PreclinicalSmall molecule

TTango Therapeutics, Inc.

TNG462 is one of 51 small molecule programs targeting Efficacy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EfficacyRecruiting

MTAP-Deleted Solid TumorsActive, not recruiting

EfficacyPreclinical

Recruiting

MTAP-Deleted Solid TumorsPreclinical

Active, not recruiting

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Rayos

RRoxane Laboratories

Phase 3

5 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

3 4

Alimta

SShawn Eagle

Phase 3

3 5

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 6

Levocept

SSebela Women's Health Inc.

Phase 3

1 7

Cetaphil

GGalderma R&D

Phase 3

1 8

Veracept

SSebela Women's Health Inc.

Phase 3

1 9

Aralen

Sanofi

Preclinical

2 10

Primaquine

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalActive, not recruiting

MTAP-Deleted Solid Tumors

NCT06188702

Q4 2027

PreclinicalRecruiting

PDAC

NCT06922591

Q2 2028

PreclinicalRecruiting

Locally Advanced Solid Tumor

NCT05732831

Clinical

Trials by Indication[1]

PDAC1 trial

A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation

Recruiting·TTango Therapeutics, Inc.·Preclinical·NCT06922591·183 enrolled

MTAP-deleted Solid Tumors1 trial

A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP

Active, not recruiting·SServier Bio-Innovation LLC·Preclinical·NCT06188702·61 enrolled

Locally Advanced Solid Tumor1 trial

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

Recruiting·TTango Therapeutics, Inc.·Preclinical·NCT05732831·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TNG462. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TNG462 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TNG462. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tango Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTango Therapeutics, Inc.

TNG462

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q2 2028

Trials by Indication[1]

PDAC1 trial

MTAP-deleted Solid Tumors1 trial

Locally Advanced Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News